PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28261100-1 2017 The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). aea 323-349 cannabinoid receptor 1 Homo sapiens 252-255 27062913-10 2017 These results indicate that AEA modulates the pro-aversive effects of intra-VMHdm-bicuculline treatment, recruiting CB1 cannabinoid receptors and the TRPV1 channel is involved in the AM251-related potentiation of bicuculline effects on non-oriented escape behaviour. aea 28-31 cannabinoid receptor 1 Homo sapiens 116-119 25995819-8 2015 The effect of AEA on PPARgamma in hBM-MSCs may prevail over that on the CB1 receptor mediated signal transduction, giving rise to the AEA-induced promotion of adipogenesis. aea 134-137 cannabinoid receptor 1 Homo sapiens 72-75 27516570-9 2016 Both AEA and 2-AG are primarily agonists of the CB1 receptor and to a lower degree CB2 and TRPV1r eceptors, but 2-AG has stronger affinity for these receptors. aea 5-8 cannabinoid receptor 1 Homo sapiens 48-51 25568329-5 2015 We demonstrate that microglial extracellular vesicles carry on their surface N-arachidonoylethanolamine (AEA), which is able to stimulate type-1 cannabinoid receptors (CB1), and inhibit presynaptic transmission, in target GABAergic neurons. aea 77-103 cannabinoid receptor 1 Homo sapiens 168-171 25568329-5 2015 We demonstrate that microglial extracellular vesicles carry on their surface N-arachidonoylethanolamine (AEA), which is able to stimulate type-1 cannabinoid receptors (CB1), and inhibit presynaptic transmission, in target GABAergic neurons. aea 105-108 cannabinoid receptor 1 Homo sapiens 168-171 25003845-2 2014 The best-known mammalian compound of this class is anandamide, N-arachidonoylethanolamine, one of the endogenous ligands of cannabinoid CB1 and CB2 receptors. aea 63-89 cannabinoid receptor 1 Homo sapiens 136-139 22850591-1 2012 The endocannabinoid anandamide (N-arachidonoylethanolamine, AEA), a physiologically occurring bioactive compound on CB1 and CB2 receptors, has multiple physiological functions. aea 32-58 cannabinoid receptor 1 Homo sapiens 116-119 24494681-2 2014 Increasing tissue levels of the CB1 receptor endogenous ligand N-arachidonoylethanolamine (anandamide), by inhibiting anandamide degradation through blocking the anandamide-hydrolysing enzyme fatty acid amide hydrolase, has been suggested to be used to activate the CB1 receptor. aea 63-89 cannabinoid receptor 1 Homo sapiens 32-35 24494681-2 2014 Increasing tissue levels of the CB1 receptor endogenous ligand N-arachidonoylethanolamine (anandamide), by inhibiting anandamide degradation through blocking the anandamide-hydrolysing enzyme fatty acid amide hydrolase, has been suggested to be used to activate the CB1 receptor. aea 63-89 cannabinoid receptor 1 Homo sapiens 266-269 23512546-2 2013 The principal ligands of the endocannabinoid system are the lipid transmitters N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), which activate the two major cannabinoid receptors, CB1 and CB2. aea 79-105 cannabinoid receptor 1 Homo sapiens 206-209 23169348-11 2013 Both CB(1) (by AEA and 2-AG) and non-CB(1) (by OEA) targets can alter the excitability and activity of the dopaminergic neurons in the VTA. aea 15-18 cannabinoid receptor 1 Homo sapiens 5-10 22947916-6 2013 Endocannabinoids such as anandamide [N-arachidonoylethanolamine (AEA)] and 2-arachidonoyl glycerol (2-AG) are known as orexigenic mediators that act via cannabinoid receptor 1 (CB1) in the hypothalamus and limbic forebrain to induce appetite and stimulate food intake. aea 37-63 cannabinoid receptor 1 Homo sapiens 153-175 22947916-6 2013 Endocannabinoids such as anandamide [N-arachidonoylethanolamine (AEA)] and 2-arachidonoyl glycerol (2-AG) are known as orexigenic mediators that act via cannabinoid receptor 1 (CB1) in the hypothalamus and limbic forebrain to induce appetite and stimulate food intake. aea 37-63 cannabinoid receptor 1 Homo sapiens 177-180 22947916-6 2013 Endocannabinoids such as anandamide [N-arachidonoylethanolamine (AEA)] and 2-arachidonoyl glycerol (2-AG) are known as orexigenic mediators that act via cannabinoid receptor 1 (CB1) in the hypothalamus and limbic forebrain to induce appetite and stimulate food intake. aea 65-68 cannabinoid receptor 1 Homo sapiens 153-175 22947916-6 2013 Endocannabinoids such as anandamide [N-arachidonoylethanolamine (AEA)] and 2-arachidonoyl glycerol (2-AG) are known as orexigenic mediators that act via cannabinoid receptor 1 (CB1) in the hypothalamus and limbic forebrain to induce appetite and stimulate food intake. aea 65-68 cannabinoid receptor 1 Homo sapiens 177-180 22850591-1 2012 The endocannabinoid anandamide (N-arachidonoylethanolamine, AEA), a physiologically occurring bioactive compound on CB1 and CB2 receptors, has multiple physiological functions. aea 60-63 cannabinoid receptor 1 Homo sapiens 116-119 19942623-6 2010 The DOX-induced MAPK activation and cell death were significantly enhanced when DOX was co-administered with CB1 agonists AEA or HU210. aea 122-125 cannabinoid receptor 1 Homo sapiens 109-112 22595113-10 2012 AEA-induced MMP-2 production was blocked by CB1 or TRPV1 antagonists and by small interfering RNA for CB1 or TRPV1. aea 0-3 cannabinoid receptor 1 Homo sapiens 44-47 22595113-10 2012 AEA-induced MMP-2 production was blocked by CB1 or TRPV1 antagonists and by small interfering RNA for CB1 or TRPV1. aea 0-3 cannabinoid receptor 1 Homo sapiens 102-105 22595113-12 2012 CONCLUSIONS: We demonstrated for the first time that AEA induced MMP-2 production via CB1 and TRPV1 in HPC. aea 53-56 cannabinoid receptor 1 Homo sapiens 86-89 21562266-1 2011 Two endogenous ligands for cannabinoid CB1 receptors, anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol (2-AG), have been identified and characterized. aea 66-92 cannabinoid receptor 1 Homo sapiens 39-42 20590572-6 2010 The AEA- or HU210-induced cell death and MAPK activation were attenuated by CB(1) antagonists [SR141716 (rimonabant) and AM281], inhibitors of p38 and JNK-MAPKs or the antioxidant N-acetylcysteine. aea 4-7 cannabinoid receptor 1 Homo sapiens 76-81 22447182-4 2012 Further, the studied human melanoma cell lines expressed functional CB1 since physiological and synthetic ligands, anandamide (AEA), Met-F-AEA, ACEA and AM251 showed a wide range of biological effects in vitro, for example anti-proliferative, proapoptotic and anti-migratory. aea 127-130 cannabinoid receptor 1 Homo sapiens 68-71 22593077-7 2012 Intraplantar injection of AEA (10 mug/10 mul) or URB597 (9 mug/10 mul) transiently attenuated hyperalgesia through activation of peripheral CB1 receptors. aea 26-29 cannabinoid receptor 1 Homo sapiens 140-143 22087025-1 2012 The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor that is activated in an autocrine fashion by the endocannabinoids (EC), N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG). aea 142-168 cannabinoid receptor 1 Homo sapiens 4-36 22087025-1 2012 The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor that is activated in an autocrine fashion by the endocannabinoids (EC), N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG). aea 170-173 cannabinoid receptor 1 Homo sapiens 4-36 21185816-5 2011 These simulations are compared with a 70 ns simulation of the cannabinoid CB1 receptor endogenous ligand, N-arachidonoylethanolamine (anandamide, AEA) in a POPC bilayer. aea 106-132 cannabinoid receptor 1 Homo sapiens 74-77 19942623-7 2010 Remarkably, cell death and MAPK activation induced by AEA, HU210, and DOX +/- AEA/HU210 were largely attenuated by either CB1 antagonists (rimonabant and AM281) or by inhibitors of p38 and JNK MAPKs. aea 54-57 cannabinoid receptor 1 Homo sapiens 122-125 19942623-7 2010 Remarkably, cell death and MAPK activation induced by AEA, HU210, and DOX +/- AEA/HU210 were largely attenuated by either CB1 antagonists (rimonabant and AM281) or by inhibitors of p38 and JNK MAPKs. aea 78-81 cannabinoid receptor 1 Homo sapiens 122-125 17118807-4 2006 Cannabinoid type-1 (CB1) and CB2 receptors belong to the family of G protein-coupled receptors and are the primary targets of the endogenous cannabinoids N-arachidonoyl ethanolamine and 2-arachidonoyl glyerol. aea 154-181 cannabinoid receptor 1 Homo sapiens 20-23 19285258-5 2009 The cannabinoid receptor type 1 (CB1), one of the two identified cannabinoid receptors, is expressed in energy-balance brain structures that are also able to readily produce or inactivate N-arachidonoyl ethanolamine (anandamide) and 2-arachidonoylglycerol (2AG), the most abundantly formed and released endocannabinoids. aea 188-215 cannabinoid receptor 1 Homo sapiens 33-36 17965731-1 2008 BACKGROUND AND PURPOSE: N-arachidonoyl ethanolamine (AEA) and 2-arachidonoyl glycerol (2-AG) are endogenous cannabinoids binding to the cannabinoid receptors CB1 and CB2 to modulate neuronal excitability and synaptic transmission in primary afferent neurons. aea 24-51 cannabinoid receptor 1 Homo sapiens 158-161 17965731-1 2008 BACKGROUND AND PURPOSE: N-arachidonoyl ethanolamine (AEA) and 2-arachidonoyl glycerol (2-AG) are endogenous cannabinoids binding to the cannabinoid receptors CB1 and CB2 to modulate neuronal excitability and synaptic transmission in primary afferent neurons. aea 53-56 cannabinoid receptor 1 Homo sapiens 158-161 17965731-10 2008 The observed co-localization of AEA, 2-AG, and their synthetic enzymes with the reported localization of CB1 raises the possibility of intrinsic-autocrine signalling within lipid raft domains and/or retrograde-paracrine signalling. aea 32-35 cannabinoid receptor 1 Homo sapiens 105-108 16596770-10 2005 As well as acting on CB1 and CB2 receptors, there is convincing evidence that anandamide can activate transient receptor potential vanilloid type 1 (TRPV1) receptors. aea 78-88 cannabinoid receptor 1 Homo sapiens 21-24 16099396-1 2005 The endocannabinoid anandamide (N-arachidonoylethanolamine) was proposed to be an extracellular retrograde messenger, which regulates excitability of neurons by cannabinoid CB1 receptor-dependent inhibition of neurotransmitter release. aea 32-58 cannabinoid receptor 1 Homo sapiens 173-176 14645706-3 2003 One potentially important mechanism involves signaling between an evolutionarily conserved G protein-coupled protein cannabinoid receptor, CB1, that is expressed at high levels on the surface of the trophectoderm and anandamide (N-arachi-donoylethanolamine), an endocannabinoid ligand found to be produced at higher levels by the uterus before implantation and then down-regulated at the time of implantation. aea 229-256 cannabinoid receptor 1 Homo sapiens 139-142 10785538-4 2000 Both AEA and 2-AG bind to the neuronal form of the cannabinoid receptor (CB1). aea 5-8 cannabinoid receptor 1 Homo sapiens 73-76 10734181-1 2000 N-Arachidonoylethanolamine (AEA) is a proposed endogenous ligand of the central cannabinoid receptor (CB1). aea 0-26 cannabinoid receptor 1 Homo sapiens 102-105 10734181-1 2000 N-Arachidonoylethanolamine (AEA) is a proposed endogenous ligand of the central cannabinoid receptor (CB1). aea 28-31 cannabinoid receptor 1 Homo sapiens 102-105 10336536-3 1999 We have synthesized two analogs of N-arachidonylethanolamine (AEA), arachidonylcyclopropylamide (ACPA) and arachidonyl-2-chloroethylamide (ACEA), that bind to the CB1 receptor with very high affinity (KI values of 2.2 +/- 0.4 nM and 1.4 +/- 0.3 nM, respectively) and to the CB2 receptor with low affinity (KI values of 0.7 +/- 0.01 microM and 3.1 +/- 1.0 microM, respectively). aea 62-65 cannabinoid receptor 1 Homo sapiens 163-166 10469888-2 1999 N- Arachidonoylethanolamine (anandamide) and some of its polyunsaturated congeners have been found in mammalian brain and shown to activate the CB1 and, with a lower efficacy, CB2 cannabinoid receptor subtypes. aea 0-27 cannabinoid receptor 1 Homo sapiens 144-147 10336536-6 1999 Therefore, ACPA and ACEA are high-affinity agonists of the CB1 receptor but do not bind the CB2 receptor, suggesting that structural analogs of AEA can be designed with considerable selectivity for the CB1 receptor over the CB2 receptor. aea 144-147 cannabinoid receptor 1 Homo sapiens 59-62 10336536-6 1999 Therefore, ACPA and ACEA are high-affinity agonists of the CB1 receptor but do not bind the CB2 receptor, suggesting that structural analogs of AEA can be designed with considerable selectivity for the CB1 receptor over the CB2 receptor. aea 144-147 cannabinoid receptor 1 Homo sapiens 202-205 34282702-2 2021 N-Arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) represent two major endocannabinoids in the human body and they exert many of their cellular and organ system effects by activating the Gi/o protein-coupled, cannabinoid type 1 (CB1) and type 2 (CB2) receptors. aea 0-26 cannabinoid receptor 1 Homo sapiens 257-260 34282702-2 2021 N-Arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) represent two major endocannabinoids in the human body and they exert many of their cellular and organ system effects by activating the Gi/o protein-coupled, cannabinoid type 1 (CB1) and type 2 (CB2) receptors. aea 40-43 cannabinoid receptor 1 Homo sapiens 257-260 30126012-1 2018 BACKGROUND AND OBJECTIVES: The endogenous cannabinoid anandamide (AEA), an agonist at type-1 cannabinoid (CB1) receptors, is metabolized by fatty acid amide hydrolase (FAAH). aea 66-69 cannabinoid receptor 1 Homo sapiens 106-109 35490598-5 2022 Transcript analysis of angiogenic factors of the vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) protein family demonstrated the ability of AEA to increase VEGF-C and VEGFR3 expression via cannabinoid receptors CB1 and CB2 while the placental growth factor (PlGF) was increased through CB1. aea 169-172 cannabinoid receptor 1 Homo sapiens 240-243 35490598-5 2022 Transcript analysis of angiogenic factors of the vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) protein family demonstrated the ability of AEA to increase VEGF-C and VEGFR3 expression via cannabinoid receptors CB1 and CB2 while the placental growth factor (PlGF) was increased through CB1. aea 169-172 cannabinoid receptor 1 Homo sapiens 315-318 33362550-1 2020 Classically, the endocannabinoid system (ECS) consists of endogenous lipids, of which the best known are anandamide (AEA) and 2 arachidonoylglycerol (2-AG), their enzyme machinery for synthesis and degradation and their specific receptors, cannabinoid receptor one (CB1) and cannabinoid receptor two (CB2). aea 117-120 cannabinoid receptor 1 Homo sapiens 266-269 31923023-10 2020 These results suggest that the possible interaction between receptors CB1 and T1R3 has consequences not only in taste perception but also that AEA intervenes in the activity of dopaminergic nuclei such as the NAc, and that the chronic administration AEA and sucralose intake induce long-term changes in the reward system. aea 250-253 cannabinoid receptor 1 Homo sapiens 70-73 30739035-2 2019 Inhibition of fatty-acid amide hydrolase (FAAH), the major enzyme catalyzing the degradation of anandamide (AEA), an endocannabinoid, and other fatty-acid amides, suppresses pain without unwanted side effects typical of direct CB1 agonists. aea 108-111 cannabinoid receptor 1 Homo sapiens 227-230 30460698-9 2018 SR144528, an antagonist of type 2 cannabinoid receptor (CB2), has a less-potent effect, suggesting that the CB1 receptor is overall involved in the AEA effect. aea 148-151 cannabinoid receptor 1 Homo sapiens 108-111